Skip to content

The research of the mechanism of postprandial hypotension and acarbose in the treatment in elder diabetes mellitus

Effectiveness of acarbose in treating elder diabetic patients with postprandial hypotension

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15006177
Enrollment
Unknown
Registered
2015-04-03
Start date
2012-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postprandial hypotension

Interventions

diabetic patients with poatprandial hypotension:acarbose100mg
Placebo:placebo
DM patients without low blood pressure:N/A

Sponsors

Beijing Hospital of Ministry of Public Health
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: All patients were diagnosed with type 2 diabetes according to 1999 World Health Organization (WHO) criteria, aged between 60 and 80 years, and were receiving insulin treatment but not receiving oral anti-diabetic drugs treatment. Glycohemoglobin (HbA1c) values were between 7% and 11%.Postprandial hypotension (PPH) was defined as a decrease in systolic blood pressure of >=20 mm Hg or a decrease below 90 mm Hg from a pressure of >=100 mm Hg within 2 hours after a meal.

Exclusion criteria

Exclusion criteria: Exclusion criteria were: a history of renal disease with a plasma creatinine concentration of 133 umol/L (1.5 mg/dL) or more; severe gastrointestinal diseases; severe cardiac diseases (a history of unstable angina or myocardial infarction within the previous 6 months or New York Heart Association class III or IV congestive heart failure); hepatic diseases, or an aspartate aminotransferase or alanine aminotransferase concentration at least twice as high as the upper limit of the normal range; endocrine diseases (hypothyroidism, hyperthyroidism, Cushing's syndrome); uncontrolled hypertension (systolic blood pressure >=160mmHg or diastolic blood pressure >=95mmHg) or using drugs that can affect the blood pressure or heart rate such as cardio-active drugs or antihypertensive drugs (e.g., digitalis, diuretics, anti-angina agents, ACEI/ARB, beta-blockers, or CCB).

Design outcomes

Primary

MeasureTime frame
postprandial hypotension;

Secondary

MeasureTime frame
heart rate variability;

Countries

China

Contacts

Public ContactLixin Guo
glx1218@163.com+86 13901317569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 27, 2026